945947-99-9

Basic information

• Product Name: 3-oxa-1,8-diazaspiro[4.5]decan-2-one
• Synonyms: 3-oxa-1,8-diazaspiro[4.5]decan-2-one;3 - oxa - 1,8 - diazaspiro[4.5]decan - 2 - one 945892-90-0 HCl
• CAS NO: 945947-99-9
• Molecular Formula: C7H12N2O2
• Molecular Weight: 156.18238
• Mol File: 945947-99-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-oxa-1,8-diazaspiro[4.5]decan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxa-1,8-diazaspiro[4.5]decan-2-one(945947-99-9)
• EPA Substance Registry System: 3-oxa-1,8-diazaspiro[4.5]decan-2-one(945947-99-9)

Safety Data

• Hazardous Substances Data: 945947-99-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-oxa-1,8-diazaspiro[4.5]decan-2-one is used as a drug lead for its demonstrated biological activity, making it a candidate for the development of new pharmaceuticals. Its unique structure allows it to be a potential starting point for creating novel therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-oxa-1,8-diazaspiro[4.5]decan-2-one is utilized as a subject of study to understand its properties and how they can be harnessed to create effective medicines. Its structure is of particular interest for the design of new drug molecules.
Used as a Building Block in Organic Synthesis:
3-oxa-1,8-diazaspiro[4.5]decan-2-one is used as a building block in the synthesis of other biologically active compounds. Its spiro ring system provides a structural foundation that can be modified or expanded upon to create a variety of complex organic molecules with potential applications in medicine and other fields.

Upstream product

• 312928-52-2 (4-amino-1-benzyl-piperidin-4-yl)-methanol 
• 39143-25-4 1-benzyl-4-amino-4-piperidinecarboxylic acid 
• 945892-89-7 8-benzyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one 

Relevant articles and documents

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

SUBSTITUTED QUINOLONES III

The invention relates to substituted quinolones and to methods for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.